Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04467060
Other study ID # 3571-CPK-1001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 14, 2014
Est. completion date June 25, 2015

Study information

Verified date June 2014
Source Sihuan Pharmaceutical Holdings Group Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single-center, randomized, open-labeled, 2×2 crossover phase 1 study to evaluate the pharmakinetics effect of high fat food to single dose administration of Anaprazole in healthy Chinese male subjects. 14 health male subjects is divided to A group (n=7) and B group (n=7). 2 periods (7 days) cross-over design, anaprazole 40mg single dose, one is fasting oral administration before breakfast, the other is oral administration 30 minutes after breakfast with high fat food.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date June 25, 2015
Est. primary completion date June 25, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. The subject is capable of understanding and complying with protocol requirements, and signed and dated a written informed consent form voluntarily;

2. The subject is a Chinese health adult, aged 18 to 45 years, inclusive;

3. The subject weighed at least 50.0 kg and had a body mass index (BMI) between 19.0 kg/m^2 and 25.0 kg/m^2, inclusive;

4. Has clinical laboratory evaluations, vital signs and ECG testing within the reference range, and medical history and physicial examination results are normal. Participants with evaluations outside the reference range that are deemed not clinically significant by the investigator may be included at investigator discretion

5. No medical history of allergy to proton pump inhibitors and no any other drug allergy history;

6. The subjects have a good lifestyle and can keep good communication with the investigators and comply with the requirements of clinical trial.

Exclusion Criteria:

1. Has postural hypotension, gastrointestinal disease (gastric ulcer, gastritis and etc), liver disease, renal disease (nephritis, pyelonephritis and etc), and other disease or medical history of any other system (cardiovascular, respiratory, psychoneural, hematology, endocrinology and etc) ;

2. Has clinical significant abnormal electrolytes (especially hypopotassemia) in screening examination;

3. Has clinical significant ECG abnormal history or family history of long QT syndrome(Grandparents, parents and siblings);

4. Has rhinitis, allergic rhinitis, recurrent hemorrhinia, nasal deformity and abnormal nasal septum;

5. With positive result of drug screening test;

6. With positive result of nicotine test;

7. Female participants who are pregnant, breast-feeding or menstral period, or participants has no effective contraception method, or has pregnancy plan in 6 months;

8. Has received any drugs: acid-inhibitors, any priscription drug, herb medicine, non-prescription drugs and/or food suppliments (including vitamine) within 2 weeks before randomization;

9. Blood donation / blood loss =400 mL within 3 months, or participated any other clinical trials within 3 months;

10. Known Human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, and Treponema pallidum specific antibody test results were positive at screening;

11. Frequent alcoholics (drink more than 2 units of alcohol per day, 1 unit = 330 mL beer or 25 mL liquor or 125 mL wine), or took food or drinks with alcoholics 72 hours before randomization;

12. Has taken foods or drinks with xanthine(cafeine) or intensive excercise. Has taken foods or drinks that affect CYP3A4 (such as grapefruit or beverages containing grapefruit) within 14 days before administration of investigational drugs;

13. Smoke more than 5 pieces per week;

14. Any conditions in which considered by investigator not be appropriate to participate in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anaprazole Sodium
2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg,fasting oral administration.
Placebo
single dose, fasting oral administration

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sihuan Pharmaceutical Holdings Group Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0 All adverse events will be monitored in each subject From signing informed consent to study completion, 8 days post-dose
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01606462 - Oxytocin and Social Cognition Phase 1
Completed NCT01382017 - Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study N/A